Alpha Tau Medical DRTS
NASDAQ DRTS
$15.03 +0.41 (+2.80%)
As of: Sep 4, 2026 · 3:59 PM EDT

Alpha Tau Medical (DRTS) Net Income towards Common Stockholders (2021 - 2026)

Alpha Tau Medical (DRTS) posted Net Income towards Common Stockholders of $22.9 million for Q1 2026, up 87.93% sequentially from $12.2 million in Q4 2025, and up 166.98% YoY from $8.6 million in Q1 2025.

Analysis

Alpha Tau Medical (DRTS) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Alpha Tau Medical has reported Net Income towards Common Stockholders for 6 years, with the latest figure at $22.9 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 166.98% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.8 million (up 75.67% YoY) and the FY2025 annual result came in at $42.4 million, up 33.55% from the prior year.
  • Net Income towards Common Stockholders improved to $22.9 million in Q1 2026 per DRTS's latest filing, from $12.2 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $25.7 million in Q1 2022 and troughed at $2.0 million in Q2 2022.
  • A 5-year average of $9.4 million and a median of $8.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 71.42% in 2022, then soared 334.88% in 2023.
  • Over 5 years, Net Income towards Common Stockholders stood at $3.4 million in 2022, then soared by 116.78% to $7.3 million in 2023, then advanced by 28.89% to $9.5 million in 2024, then advanced by 28.86% to $12.2 million in 2025, then soared by 87.93% to $22.9 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $22.9 million, $12.2 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Alpha Tau Medical 1.21 Bn 1.11 Bn - 45.36 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 45.36 Mn
Mar 31, 2026 22.96 Mn
Dec 31, 2025 12.21 Mn
Sep 30, 2025 11.70 Mn
Jun 30, 2025 9.98 Mn
Mar 31, 2025 8.49 Mn
Dec 31, 2024 9.47 Mn
Sep 30, 2024 6.92 Mn
Jun 30, 2024 7.36 Mn
Mar 31, 2024 7.98 Mn
Dec 31, 2023 7.35 Mn
Sep 30, 2023 4.99 Mn
Jun 30, 2023 8.64 Mn
Mar 31, 2023 8.15 Mn
Dec 31, 2022 3.39 Mn
Sep 30, 2022 2.61 Mn
Jun 30, 2022 1.99 Mn
Mar 31, 2022 25.74 Mn
Dec 31, 2021 3.81 Mn
Sep 30, 2021 4.81 Mn